New drug ADX-038 aims to control rare kidney diseases
NCT ID NCT06989359
First seen Jan 24, 2026 · Last updated May 12, 2026 · Updated 14 times
Summary
This study tests a new drug called ADX-038 in 45 adults with kidney diseases caused by an overactive complement system (part of the immune system), including IgA nephropathy and C3G. The goal is to see if the drug is safe and can help control the disease. Participants must have active kidney disease and be on standard supportive care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGAN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ADARx Clinical Site
RECRUITINGDoral, Florida, 33122, United States
-
ADARx Clinical Site
RECRUITINGMiami, Florida, 33127, United States
-
ADARx Clinical Site
RECRUITINGPembroke Pines, Florida, 33029, United States
-
ADARx Clinical Site
RECRUITINGIowa City, Iowa, 52242, United States
-
ADARx Clinical Site
RECRUITINGShreveport, Louisiana, 71101, United States
-
ADARx Clinical Site
RECRUITINGShelby, Michigan, 48315, United States
-
ADARx Clinical Site
RECRUITINGGreat Neck, New York, 11021, United States
-
ADARx Clinical Site
RECRUITINGColumbus, Ohio, 43210, United States
-
ADARx Clinical Site
RECRUITINGDakota Dunes, South Dakota, 57049, United States
-
ADARx Clinical Site
RECRUITINGDallas, Texas, 75230, United States
-
ADARx Clinical Site
RECRUITINGHouston, Texas, 77027, United States
-
ADARx Clinical Site
RECRUITINGWollongong, New South Wales, 2500, Australia
-
ADARx Clinical Site
RECRUITINGSydney, NSW 2139, Australia
-
ADARx Clinical Site
RECRUITINGWoolloongabba, QLD 4102, Australia
-
ADARx Clinical Site
RECRUITINGHong Kong, 2500, Hong Kong
-
ADARx Clinical Site
RECRUITINGShatin, Hong Kong
-
ADARx Clinical Site
RECRUITINGCheonan, 31151, South Korea
-
ADARx Clinical Site
RECRUITINGDaegu, 42601, South Korea
-
ADARx Clinical Site
RECRUITINGGyeonggi-do, 05278, South Korea
-
ADARx Clinical Site
RECRUITINGSeoul, 02841, South Korea
-
ADARx Clinical Site
RECRUITINGSeoul, 03080, South Korea
-
ADARx Clinical Site
RECRUITINGSeoul, 03722, South Korea
-
ADARx Clinical Site
RECRUITINGSeoul, 05278, South Korea
-
ADARx Clinical Site
RECRUITINGMadrid, 28041, Spain
-
ADARx Clinical Site
RECRUITINGNewcastle upon Tyne, UK, NE7 7DN, United Kingdom
Conditions
Explore the condition pages connected to this study.